Stock Track | CorMedix Soars 9.47% Pre-Market on Stellar Q3 Results and Raised Guidance

Stock Track11-12

CorMedix Inc. (CRMD) shares surged 9.47% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results and an optimistic outlook for the full year.

The biopharma company reported a Q3 earnings per share (EPS) of $1.26, significantly outperforming the analysts' estimate of $0.65. Net income for the quarter reached $108.6 million, nearly doubling the expected $54.7 million. CorMedix also posted robust net revenue of $104.3 million for the quarter.

Driving this strong performance was the higher-than-anticipated utilization of DefenCath by outpatient dialysis customers, which contributed $88.8 million to the net revenue. The company's integration of Melinta Therapeutics is reportedly ahead of schedule, capturing synergies of approximately $30 million.

In light of these positive results, CorMedix has raised its full-year 2025 guidance. The company now expects pro forma net revenue to be in the range of $390 to $410 million, up from its previous forecast. Additionally, CorMedix increased its 2025 pro forma adjusted EBITDA guidance to $220-$240 million.

The market's enthusiastic response to these results and the improved outlook underscores investor confidence in CorMedix's growth trajectory and operational efficiency. As the company continues to expand its product utilization and realize synergies from recent acquisitions, it appears well-positioned for sustained growth in the biopharmaceutical sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1180427284?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 20:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1180427284","market":"sg","top_or_hot":-1,"title":"Stock Track | CorMedix Soars 9.47% Pre-Market on Stellar Q3 Results and Raised Guidance","media":"Stock Track","content":"<p>CorMedix Inc. (CRMD) shares surged 9.47% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results and an optimistic outlook for the full year.</p>\n\n<p>The biopharma company reported a Q3 earnings per share (EPS) of $1.26, significantly outperforming the analysts' estimate of $0.65. Net income for the quarter reached $108.6 million, nearly doubling the expected $54.7 million. CorMedix also posted robust net revenue of $104.3 million for the quarter.</p>\n\n<p>Driving this strong performance was the higher-than-anticipated utilization of DefenCath by outpatient dialysis customers, which contributed $88.8 million to the net revenue. The company's integration of Melinta Therapeutics is reportedly ahead of schedule, capturing synergies of approximately $30 million.</p>\n\n<p>In light of these positive results, CorMedix has raised its full-year 2025 guidance. The company now expects pro forma net revenue to be in the range of $390 to $410 million, up from its previous forecast. Additionally, CorMedix increased its 2025 pro forma adjusted EBITDA guidance to $220-$240 million.</p>\n\n<p>The market's enthusiastic response to these results and the improved outlook underscores investor confidence in CorMedix's growth trajectory and operational efficiency. As the company continues to expand its product utilization and realize synergies from recent acquisitions, it appears well-positioned for sustained growth in the biopharmaceutical sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CorMedix Soars 9.47% Pre-Market on Stellar Q3 Results and Raised Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CorMedix Soars 9.47% Pre-Market on Stellar Q3 Results and Raised Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-12 20:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CorMedix Inc. (CRMD) shares surged 9.47% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results and an optimistic outlook for the full year.</p>\n\n<p>The biopharma company reported a Q3 earnings per share (EPS) of $1.26, significantly outperforming the analysts' estimate of $0.65. Net income for the quarter reached $108.6 million, nearly doubling the expected $54.7 million. CorMedix also posted robust net revenue of $104.3 million for the quarter.</p>\n\n<p>Driving this strong performance was the higher-than-anticipated utilization of DefenCath by outpatient dialysis customers, which contributed $88.8 million to the net revenue. The company's integration of Melinta Therapeutics is reportedly ahead of schedule, capturing synergies of approximately $30 million.</p>\n\n<p>In light of these positive results, CorMedix has raised its full-year 2025 guidance. The company now expects pro forma net revenue to be in the range of $390 to $410 million, up from its previous forecast. Additionally, CorMedix increased its 2025 pro forma adjusted EBITDA guidance to $220-$240 million.</p>\n\n<p>The market's enthusiastic response to these results and the improved outlook underscores investor confidence in CorMedix's growth trajectory and operational efficiency. As the company continues to expand its product utilization and realize synergies from recent acquisitions, it appears well-positioned for sustained growth in the biopharmaceutical sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRMD","symbol_name":"CorMedix Inc.","start_time":0,"source_url":"","article_id":"1180427284","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1180427284","pubTimestamp":1762951706,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"CorMedix Inc. (CRMD) shares surged 9.47% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results and an optimistic outlook for the full year....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRMD":"CorMedix Inc."},"translate_title":"股票追踪|CorMedix盘前飙升9.47%，因第三季度业绩出色并上调指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRMD":1},"content_text":"CorMedix Inc. (CRMD) shares surged 9.47% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results and an optimistic outlook for the full year.\nThe biopharma company reported a Q3 earnings per share (EPS) of $1.26, significantly outperforming the analysts' estimate of $0.65. Net income for the quarter reached $108.6 million, nearly doubling the expected $54.7 million. CorMedix also posted robust net revenue of $104.3 million for the quarter.\nDriving this strong performance was the higher-than-anticipated utilization of DefenCath by outpatient dialysis customers, which contributed $88.8 million to the net revenue. The company's integration of Melinta Therapeutics is reportedly ahead of schedule, capturing synergies of approximately $30 million.\nIn light of these positive results, CorMedix has raised its full-year 2025 guidance. The company now expects pro forma net revenue to be in the range of $390 to $410 million, up from its previous forecast. Additionally, CorMedix increased its 2025 pro forma adjusted EBITDA guidance to $220-$240 million.\nThe market's enthusiastic response to these results and the improved outlook underscores investor confidence in CorMedix's growth trajectory and operational efficiency. As the company continues to expand its product utilization and realize synergies from recent acquisitions, it appears well-positioned for sustained growth in the biopharmaceutical sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1180427284","isCrawlerRequest":true}